STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025




STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025

DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc.

A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025.

For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 6, 2025, either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 2170300 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally.

About STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.   For more information, visit www.steris.com.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

Julie_Winter@steris.com

440.392.7245

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025




STERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025

DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc.

A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025.

For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 6, 2025, either at www.steris-ir.com or via phone. To access the replay of the call, please use the access code 2170300 and dial 1-877-344-7529 in the United States or 1-412-317-0088 internationally.

About STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.   For more information, visit www.steris.com.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

Julie_Winter@steris.com

440.392.7245

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

Aveanna Announces Launch of Secondary Offering of Common Stock




Aveanna Announces Launch of Secondary Offering of Common Stock

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, announced today that certain selling stockholders affiliated with J.H. Whitney Equity Partners VII, LLC (the “Selling Stockholders”) have commenced a secondary offering of 10,000,000 shares of its common stock (the “Offering”). The Selling Stockholders will also grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of the Company’s common stock. The Selling Stockholders will receive all of the net proceeds from the Offering. The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders.

Jefferies LLC and J.P. Morgan Securities LLC are acting as joint lead book-running managers for the Offering. Barclays and RBC Capital Markets are acting as bookrunners for the Offering.

A shelf registration statement on Form S-3 (including a prospectus) relating to these securities has been filed with and declared effective by the Securities and Exchange Commission (the “SEC”). Before you invest, you should read the prospectus in that registration statement, including the documents incorporated by reference therein, the accompanying prospectus supplement and other documents the Company has filed or will file with the SEC for more complete information about the Company and this Offering. You may get these documents, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus may also be obtained, when available, by contacting Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization.

Forward-Looking Statements

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2024 fiscal year filed with the SEC on March 13, 2025, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Investor Contact

Matt Buckhalter
Chief Financial Officer
Ir@aveanna.com

Aveanna Healthcare Holdings Announces Preliminary Third Quarter Financial Results




Aveanna Healthcare Holdings Announces Preliminary Third Quarter Financial Results

ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced certain preliminary financial results for the three-month period ended September 27, 2025.

For the three-month period ended September 27, 2025, we expect to report:

• Revenue of approximately $616 million to $624 million, representing growth over the prior year third quarter of approximately 21.0% to 22.6%.
• Net income of approximately $11 million to $15 million, representing growth over the prior year third quarter of approximately 125.7% to 135.0%.
• Adjusted EBITDA of approximately $77 million to $81 million, representing growth over the prior year third quarter of approximately 61.0% to 69.3%.

Preliminary Financial Data

Our consolidated financial statements for our three-month period ended September 27, 2025 are not yet available. Accordingly, the financial and operational results we present in this press release are preliminary estimates and subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review and finalization of our consolidated financial statements. As a result, these preliminary estimated results may differ from actual results that will be reflected in our consolidated financial statements for the fiscal quarter when they are completed and publicly disclosed. These preliminary estimated results may change and those changes may be material.

Our expectations with respect to our unaudited results for the period discussed in this press release are based upon management estimates and are the responsibility of management. Our independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary results (including any financial data) and, accordingly, does not express an opinion or any other form of assurance with respect to these preliminary results.

Although the results of our three-month period ended September 27, 2025 are not yet finalized, the information included in this press release reflects our preliminary expectations with respect to such results based on currently available information.

Non-GAAP Financial Measures

In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), we also evaluate our financial performance using Adjusted EBITDA. Given our determination of adjustments in arriving at our computations, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, revenue, operating income or loss, or any other financial measures calculated in accordance with GAAP.

EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as net income or loss. Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net income or loss before interest expense, net; income tax expense or benefit; and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation and associated employer payroll taxes; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; restructuring costs; other legal matters; and other system transition costs, professional fees and other costs. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.

We believe our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, we consider both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which we do not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.

We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides us a normalized view of our core, ongoing operations after integrating our acquired companies, which we believe is an important measure in assessing our performance.

The following table reconciles net income to EBITDA and Adjusted EBITDA for the period presented.

(1) EBITDA is presented in this table solely for the purposes of reconciling to Adjusted EBITDA. Values presented in the Low and High columns may not reflect the low and high ends of the EBITDA presented on account of the income tax expense (benefit) portion of the reconciliation from net income.
(2) Represents valuation adjustments and settlements associated with interest rate derivatives that are not included in interest expense, net.
(3) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, and finance and accounting diligence and documentation.
(4) Represents (i) costs associated with our Integration Management Office, which focuses on our integration efforts and transformational projects such as systems conversions and implementations, material cost reduction and restructuring projects, among other things, of approximately $0.5 million to $0.6 million; and (ii) transitionary costs incurred to integrate acquired companies into our field and corporate operations of approximately $1.6 million to $1.7 million. Transitionary costs incurred to integrate acquired companies include IT consulting costs and related integration support costs; salary, severance and retention costs associated with duplicative acquired company personnel until such personnel are exited from the Company; accounting, legal and consulting costs; expenses and impairments related to the closure and consolidation of overlapping markets of acquired companies, including lease termination and relocation costs; costs associated with terminating legacy acquired company contracts and systems; and one-time costs associated with rebranding our acquired companies and locations to the Aveanna brand.
(5) Represents legal and forensic costs, as well as settlements associated with resolving legal matters arising during or as a result of our acquisition-related activities. This primarily includes (i) costs of approximately $1.3 million to $1.5 million to comply with the U.S. Department of Justice, Antitrust Division’s grand jury subpoena related to nurse wages and hiring activities in certain of our markets, in connection with a terminated transaction.
(6) Represents costs associated with restructuring our branch and regional administrative footprint as well as our corporate overhead infrastructure costs in order to appropriately size our resources to current volumes, including: (i) branch and regional salary and severance costs; (ii) corporate salary and severance costs; and (iii) rent and lease termination costs associated with the closure of certain office locations.
(7) Represents activity related to accrued legal settlements and the related costs and expenses associated with certain judgments and arbitration awards rendered against us where certain insurance coverage is in dispute. We released a legal reserve related to a certain accrued legal settlement during the period presented.
(8) Represents: (i) other costs or (income) that are either non-cash or non-core to the our ongoing operations of approximately $(0.1) million to $(0.2) million.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. 

Forward-Looking Statements

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and preliminary unaudited fourth quarter financial results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, among others, the risks and uncertainties set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2024 fiscal year filed with the SEC on March 13, 2025, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Investor Contact
Matt Buckhalter
Chief Financial Officer
ir@aveanna.com 

beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program




beyond|AESTHETICS Owner Leslie Petersen, NP, Accepted into Elite Dr. Mauricio de Maio MD Codes™ Fellowship Program

Camarillo, CA, Oct. 21, 2025 (GLOBE NEWSWIRE) — beyond|AESTHETICS is proud to announce that its owner, Leslie Petersen, NP, has been selected as one of only 15 individuals nationally for the highly coveted Dr. Mauricio de Maio MD Codes™ fellowship program for the 2025-2026 term. This prestigious acceptance underscores Mrs. Petersen’s commitment to excellence in the field of aesthetic medicine.

Dr. Mauricio de Maio is an internationally recognized innovator and thought leader in aesthetic medicine, whose revolutionary MD Codes system has been widely adopted as the global gold standard for facial rejuvenation using hyaluronic acid dermal fillers. The MD Codes platform, promoted by the Allergan Medical Institute™ (AMI), is renowned for its utilization of the JUVÉDERM® collection of fillers to achieve precise, natural-looking, and harmonious results.

“I am incredibly honored and excited to be accepted into Dr. de Maio’s MD Codes fellowship program,” said Leslie Petersen, NP. “This is a tremendous opportunity to learn directly from the master himself and to bring the most advanced and effective aesthetic techniques to more providers in the country and to our patients at beyond|AESTHETICS.”

Benefits for beyond|AESTHETICS and Patients

This unparalleled fellowship will significantly enhance the offerings at beyond|AESTHETICS and provide substantial benefits for its patients:

• Access to Cutting-Edge Techniques: Mrs. Petersen will gain in-depth knowledge and hands-on training in the most advanced MD Codes protocols directly from Dr. de Maio. This will translate into even more precise, effective, and natural-looking results for patients.
• Gold Standard Treatment: Patients at beyond|AESTHETICS will receive treatments based on the globally recognized gold standard for facial rejuvenation with dermal fillers, ensuring the highest level of care and optimal outcomes.
• Enhanced Expertise: The intensive training will further elevate Mrs. Petersen’s already extensive expertise, solidifying beyond|AESTHETICS’s position as a leader in aesthetic medicine in the region.
• Certified Trainer Status: Upon completion of the program, Leslie Petersen, NP, will become a certified trainer for MD Codes. This not only signifies her mastery of the system but also opens avenues for beyond|AESTHETICS to host training sessions and contribute to the education of other aesthetic professionals.
• Personalized and Harmonious Results: The MD Codes system focuses on individualized treatment plans that respect natural facial anatomy, ensuring that each patient receives a tailored approach for harmonious and aesthetically pleasing results.

beyond|AESTHETICS is dedicated to providing its patients with the safest and most effective aesthetic treatments. Leslie Petersen’s participation in the Dr. Mauricio de Maio MD Codes fellowship program reinforces this commitment and will enable the practice to deliver even higher standards of care and innovation.

About beyond|AESTHETICS

beyond|AESTHETICS is a premier aesthetic practice dedicated to providing advanced and personalized cosmetic treatments. Led by Leslie Petersen, NP, the practice focuses on natural-looking results and patient satisfaction through a comprehensive range of services.

CONTACT: Leslie Petersen, NP
Owner, beyond|AESTHETICS
Phone: 805-312-7070
Email: info@seewhatsbeyond.com
Website: www.seewhatsbeyond.com

Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.




Glo & Spa-rkle Aesthetics and Medspa Celebrates 700-Plus 5-Star Google Reviews, Cementing Rank as Best Laser Tattoo Removal Medspa in Lubbock, Texas.

Glo & Spa-rkle Aesthetics and Medical Spa achieves a significant milestone, reinforcing its commitment to excellence in aesthetic and wellness services.

Lubbock, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) — Glo & Spa-rkle Aesthetics and Medical Spa, a leading name in the aesthetic and wellness industry, proudly announces the achievement of its 700-plus 5-star Google reviews. This milestone underscores the medspa’s dedication to providing exceptional service and results, particularly in the realm of laser tattoo removal, where it has been recognized as the best laser tattoo removal service in Lubbock, Texas.

Located in the heart of Lubbock, Glo & Spa-rkle has built a reputation for excellence by offering a wide range of innovative treatments designed to enhance beauty, health, and confidence. The medspa’s comprehensive offerings include neuromodulators, laser treatments, non-surgical face and neck lifts, body contouring, advanced RF microneedling, medical weight loss programs, PDO thread lifts and dermal fillers. Additionally, the medspa specializes in regenerative therapies, such as biostimulators, exosomes, and polydeoxyribonucleotide (PDRN), to support natural healing and rejuvenation.

Glo & Spa-rkle’s commitment to personalized care and cutting-edge technology has been a cornerstone of its success. The medspa’s use of ultrasound-guided aesthetic injections of dermal fillers ensures optimal results with minimal risk, further enhancing its reputation for safety and precision.

“Achieving our 700-plus 5-star Google reviews is a testament to the hard work, exceptional customer service  and dedication of our entire team,” Fa-tia Johnson, the lead Nurse Practitioner and owner of Glo & Spa-rkle Aesthetics and Medical Spa. “We are deeply grateful to our clients for their trust and support, and we remain committed to delivering the highest quality aesthetic and wellness services.”

The recognition as the best laser tattoo removal provider in Lubbock is a reflection of Glo & Spa-rkle’s unwavering focus on client satisfaction and exceptional outcomes. The medspa’s state-of-the-art Picoway laser tattoo removal services are renowned for their effectiveness and safety, helping clients achieve clear, tattoo-free skin with confidence.

As Glo & Spa-rkle continues to grow and evolve, it remains dedicated to empowering clients to embrace their unique beauty and thrive on their wellness journey. The medspa’s mission to deliver tailored treatments in a welcoming, judgment-free environment has resonated with clients, as evidenced by the overwhelming positive feedback and reviews.

Glo & Spa-rkle Aesthetics and Medical Spa looks forward to continuing its tradition of excellence, setting new standards in the aesthetic and wellness industry, and celebrating many more milestones in the future.

About Glo & Spa-rkle Aesthetics and Medical Spa

Glo & Spa-rkle is a premier aesthetic and wellness med spa located in Lubbock, Texas, dedicated to enhancing beauty, health, and confidence through innovative, high-quality treatments. Catering directly to clients, we offer a curated selection of services designed to promote skin and body rejuvenation, fostering a renewed sense of self-assurance. Our comprehensive offerings include neuromodulators, laser treatments, non-surgical face and neck lifts with PDO threads and EMFACE, body contouring, advanced RF microneedling, medical weight loss programs, and dermal fillers. Additionally, we specialize in regenerative therapies, such as biostimulators, exosomes, and polydeoxyribonucleotide (PDRN), to support natural healing and rejuvenation. For enhanced safety and precision, we utilize ultrasound-guided aesthetic injections of dermal fillers, ensuring optimal results with minimal risk. At Glo & Spa-rkle, we prioritize personalized care, leveraging cutting-edge technology to deliver tailored treatments in a welcoming, judgment-free environment. Our mission is to empower every client to embrace their unique beauty and thrive on their wellness journey. As a client-focused small to medium-sized enterprise, Glo & Spa-rkle generates revenue through direct-to-consumer aesthetic and wellness services, delivering exceptional outcomes with every visit. 

Press inquiries

Glo & Spa-rkle Aesthetics and Medical Spa
https://gloandsparkle.com
Lauren Boutwell
lauren.boutwell@gloandsparkle.com
8066423992
10607 Quaker Ave Suite 103, Lubbock Texas 79424.

The address changing in December 2025 to 4513 114th Street Lubbock, Texas 79424.

A video accompanying this announcement is available at https://www.youtube.com/embed/1DEW5zCZurQ

Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million




Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million

CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has acquired an additional $200,000 worth of Ethereum (ETH), bringing the Company’s total investment in ETH to $2 million.

This purchase was executed under Cosmos Health’s previously announced $300 million digital assets facility, which underpins the Company’s strategy to broaden and strengthen its portfolio through targeted digital asset investments.

Greg Siokas, CEO of Cosmos Health, stated: “Reaching the $2 million milestone in our Ethereum investment marks another important step in our digital asset expansion strategy. We remain steadfast in our commitment to leveraging our $300 million financing facility to further diversify and enhance our long-term asset base.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

IPSEN – Buy-back programme – Art 5 of MAR – Week 42 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 42 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 42_2025